Truist Financial analyst Jailendra Singh maintains $Evolent Health (EVH.US)$ with a buy rating, and adjusts the target price from $33 to $24.
According to TipRanks data, the analyst has a success rate of 30.3% and a total average return of -16.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
The reduction in the third-quarter performance of Evolent Health is noted as disheartening but not an isolated case given the prevailing risk climate. The essential business structure is still considered to be solid.
Evolent Health's Q3 EBITDA was significantly lower than consensus, influenced by a substantial rise in Oncology costs, witnessed both retrospectively and within the quarter. On a positive note, the company secured $200M in new run-rate business during Q3, underscoring the growing demand for specialty care management.
Evolent Health's third-quarter results were considered disappointing, with previous expectations indicating the company was positioned to recover a significant portion of higher costs via contractual rate increases. Despite this, prevailing sentiment among investors appears skeptical regarding the company's ability to achieve approximately $300M of EBITDA. Nonetheless, the prevailing opinion among analysts is that the recent developments are atypical, and there is confidence that Evolent's margins will stabilize as planned price adjustments are implemented.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
储亿银行分析师Jailendra Singh维持$Evolent Health (EVH.US)$买入评级，并将目标价从33美元下调至24美元。
根据TipRanks数据显示，该分析师近一年总胜率为30.3%，总平均回报率为-16.7%。
此外，综合报道，$Evolent Health (EVH.US)$近期主要分析师观点如下：
Evolent Health第三季度业绩的下降令人沮丧，但鉴于当前的风险环境，这并非个别情况。基本业务结构仍然被认为是稳固的。
受肿瘤学成本大幅上涨的影响，Evolent Health第三季度的息税折旧摊销前利润明显低于市场预期，无论是回顾性还是本季度内。积极的一面是，该公司在第三季度获得了2亿美元的新运营利率业务，这凸显了对专业护理管理的需求不断增长。
Evolent Health的第三季度业绩被认为令人失望，此前的预期表明，该公司有望通过提高合同利率来收回很大一部分较高的成本。尽管如此，投资者普遍对该公司实现约3亿美元息税折旧摊销前利润的能力持怀疑态度。尽管如此，分析师普遍认为，近期的事态发展并不典型，并且有信心随着计划的价格调整的实施，Evolent的利润率将稳定下来。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
